Cargando…

Efficacy of Vinflunine for Patients with Metastatic Urothelial Cancer after Immune Checkpoint Inhibitor Pretreatment—A Retrospective Multicenter Analysis

SIMPLE SUMMARY: With the introduction of immune checkpoint inhibitors (ICI) in recent years, the treatment landscape of metastatic urothelial cancer has undergone a substantial transformation. Nevertheless, disease progression after prior platinum-based chemotherapy and ICI pretreatment remains a ch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Riedel, Felix, Münker, Mara, Roghmann, Florian, Breyer, Johannes, Schnabel, Marco J., Burger, Maximilian, Sikic, Danijel, Büttner, Thomas, Ritter, Manuel, Hiller, Kiriaki, Wezel, Felix, Bolenz, Christian, Zengerling, Friedemann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220857/ https://www.ncbi.nlm.nih.gov/pubmed/35740516 http://dx.doi.org/10.3390/cancers14122850

Ejemplares similares

Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial)
por: Breyer, Johannes, et al.
Publicado: (2023)

Grainyhead-Like 3 Influences Migration and Invasion of Urothelial Carcinoma Cells
por: Wezel, Felix, et al.
Publicado: (2021)

Genomic Landscape of Vinflunine Response in Metastatic Urothelial Cancer
por: Bernardini, Alejandra, et al.
Publicado: (2022)

PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma
por: Klümper, Niklas, et al.
Publicado: (2023)

Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma
por: Morel, Armand, et al.
Publicado: (2010)

The Role of TKS5 in Chromosome Stability and Bladder Cancer Progression
por: Wang, Wenya, et al.
Publicado: (2022)

Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
por: Klümper, Niklas, et al.
Publicado: (2023)

mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants
por: Eckstein, Markus, et al.
Publicado: (2018)

Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts
por: Sikic, Danijel, et al.
Publicado: (2019)

The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine
por: Harshman, L C, et al.
Publicado: (2013)

Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis
por: Holmsten, Karin, et al.
Publicado: (2016)

Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis
por: Holmsten, Karin, et al.
Publicado: (2017)

Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)(†)
por: De Santis, M., et al.
Publicado: (2016)

Epithelial-to-Mesenchymal Transition Mediates Resistance to Maintenance Therapy with Vinflunine in Advanced Urothelial Cell Carcinoma
por: Font, Albert, et al.
Publicado: (2021)

Vinflunine in the treatment of bladder cancer
por: Bachner, Mark, et al.
Publicado: (2008)

Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer Group
por: Pistamaltzian, Nikolaos, et al.
Publicado: (2016)

From Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples
por: Facchini, Gaetano, et al.
Publicado: (2016)

Safety and Activity of Sorafenib in Addition to Vinflunine in Post‐Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial
por: Shah, Carl‐Henrik, et al.
Publicado: (2018)

Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients
por: Weyerer, Veronika, et al.
Publicado: (2021)

Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors
por: Oppolzer, Immanuel Augustin, et al.
Publicado: (2023)

Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study
por: Médioni, Jacques, et al.
Publicado: (2016)

Stathmin Potentiates Vinflunine and Inhibits Paclitaxel Activity
por: Malesinski, Soazig, et al.
Publicado: (2015)

Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy
por: Eckstein, Markus, et al.
Publicado: (2020)

Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer?
por: Wezel, Felix, et al.
Publicado: (2017)

High Androgen Receptor mRNA Expression Is Associated with Improved Outcome in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer
por: Sikic, Danijel, et al.
Publicado: (2021)

Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience
por: Retz, Margitta, et al.
Publicado: (2015)

Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract: an evidence-based review of safety, efficacy, and place in therapy
por: Brousell, Steven C, et al.
Publicado: (2018)

Shorter Leukocyte Telomere Length Is Associated with Worse Survival of Patients with Bladder Cancer and Renal Cell Carcinoma
por: Zheng, Xi, et al.
Publicado: (2021)

Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case report
por: Bordi, Paola, et al.
Publicado: (2016)

Immunotherapy in urothelial carcinoma: fade or future standard?
por: Breyer, Johannes, et al.
Publicado: (2016)

Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice
por: Castellano, Daniel, et al.
Publicado: (2014)

Comparative study of the radiosensitising and cell cycle effects of vinflunine and vinorelbine, in vitro
por: Simoens, Cindy, et al.
Publicado: (2008)

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
por: Fradet, Y, et al.
Publicado: (2019)

Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01–2014)
por: Passalacqua, Rodolfo, et al.
Publicado: (2017)

Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model
por: Holwell, S E, et al.
Publicado: (2001)

Gender-specific outcomes in immune checkpoint inhibitor therapy for advanced or metastatic urothelial cancer: a systematic review and meta-analysis
por: Schneidewind, Laila, et al.
Publicado: (2023)

An Immunological Glance on Pancreatic Ductal Adenocarcinoma
por: Melzer, Michael Karl, et al.
Publicado: (2020)

Characterization of cell death induced by vinflunine, the most recent Vinca alkaloid in clinical development
por: Kruczynski, A, et al.
Publicado: (2002)

C‐reactive protein flare‐response predicts long‐term efficacy to first‐line anti‐PD‐1‐based combination therapy in metastatic renal cell carcinoma
por: Klümper, Niklas, et al.
Publicado: (2021)

FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy
por: Sikic, Danijel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kvi25b70acuuo7d8v8k84iaif6